Uterine Cancer

Its functional role was validated through in vitro assays and a doxycycline (Dox)-inducible xenograft model...Co-culture experiments confirmed that silencing SNRPE significantly restores T cell-mediated cytotoxicity and reverses the expression of exhaustion markers. By remodeling the global splicing network, SNRPE concurrently sustained intrinsic malignant progression and extrinsic immune suppression in UCEC.

In xenografts, atorvastatin suppressed ULMS tumor growth by ~50% with minimal toxicity, as evidenced by normal serum ALT and creatinine levels and preserved organ histology. These findings identify protein geranylgeranylation as a novel therapeutic vulnerability in ULMS and support statin repurposing as a promising treatment strategy.

A disparity exists not only in genetic testing availability but also clinic attendance between the public and private healthcare systems, which likely limits the ability to diagnose hereditary cancer syndromes associated with gynaecological cancers in public healthcare hospitals.

Accurate diagnosis of this rare entity is contingent upon histopathological examination and immunohistochemical analysis. Awareness that IPEH can occur within the uterine corpus may facilitate its inclusion in preoperative differential diagnosis, thereby potentially improving diagnostic precision and alleviating patient anxiety associated with the suspicion of malignancy.

Integrated with functional analyses, these structures reveal that SLC34 transporters operate through an atypical alternating access cycle defined by coordinated elevator movements of an auxiliary gate domain. This work lays a foundational framework for understanding Pi regulation and opens new avenues for therapeutic strategies targeting disorders linked to phosphate imbalance.

P2, N=30, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Aug 2026 --> Aug 2027

However, further research is needed to explore its functions in other cancers and clarify its molecular mechanisms. Our review synthesizes current knowledge on CXorf67's biological significance, particularly in epigenetics and DNA damage, and its implications in oncogenesis.

P2, N=80, Recruiting, MacroGenics | N=60 --> 80 | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Jul 2027

These findings suggest that ITGA6 may serve as a potential diagnostic and prognostic biomarker in selected cancers and support a tumor-promoting role for ITGA6 in UVM.

P1, N=54, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: May 2026 --> Mar 2028

Intramyometrial uterine LCNEC can closely resemble adenomyosis and leiomyomas on imaging and may follow an explosive clinical course. This case highlights the diagnostic pitfalls of predominantly intramyometrial disease and underscores the importance of early suspicion, multidisciplinary reassessment when clinical and imaging findings are discordant, prompt platinum-based systemic therapy when feasible, and molecular profiling if the patient is willing to proceed.

Future challenges include the potential for ADCs to serve as maintenance therapies, and the rationale for combination strategies with immunotherapy, antiangiogenics, chemotherapy or targeted agents. As the understanding of ADC pharmacology deepens, these agents will play an increasingly central role in the rapidly evolving treatment paradigm of gynecologic cancers.